Our Approach
Our approach is disciplined and operator-led. We invest with a clear thesis, work closely alongside management, and focus on the fundamentals that compound value over a hold period:
- Revenue quality
- Operating leverage
- Disciplined capital allocation
We are not a generalist fund. Our focus on healthcare, wellness and beauty, consumer, and specialty retail means we bring sector fluency to every transaction, from initial diligence through to exit.
Our Strategy
Astra Capital manages closed-end wholesale private equity funds targeting the ANZ and Southeast Asian lower-mid-market. We pursue control and significant minority positions in businesses with:
- Established revenue and demonstrated operating history
- Founder or management teams seeking a capital and strategic partner, not simply an exit
- Clear opportunities for operational improvement, category expansion, or geographic scale
- Defensible positioning within healthcare, wellness and beauty, consumer, or specialty retail
Sector Focus
News & Insights
Research & White Papers
-
Is Epsilon Healthcare a Good Opportunity?
Epsilon Healthcare's return from administration to the ASX boards is a genuine recovery story, but thin cash, related-party funding, and unresolved governance questions mean the market is still working out...
Is Epsilon Healthcare a Good Opportunity?
Epsilon Healthcare's return from administration to the ASX boards is a genuine recovery story, but thin cash, related-party funding, and unresolved governance questions mean the market is still working out...
-
Is Fisher & Paykel Healthcare's Tariff Playbook a Model for ANZ Medtech?
FPH's record FY26 and its tariff refund show how a disciplined ANZ medtech manufacturer absorbs trade-policy shocks, a framework worth applying across Astra Capital's healthcare coverage.
Is Fisher & Paykel Healthcare's Tariff Playbook a Model for ANZ Medtech?
FPH's record FY26 and its tariff refund show how a disciplined ANZ medtech manufacturer absorbs trade-policy shocks, a framework worth applying across Astra Capital's healthcare coverage.
-
Is CSL's Reset the Bottom, or the Start of a Longer Story?
CSL's FY26 result wiped US$2.6bn off the bottom line and closed out a year of guidance cuts, a CEO exit, and a delayed demerger. We use it, and a comparable...
Is CSL's Reset the Bottom, or the Start of a Longer Story?
CSL's FY26 result wiped US$2.6bn off the bottom line and closed out a year of guidance cuts, a CEO exit, and a delayed demerger. We use it, and a comparable...
-
Is Cochlear a Reset Opportunity or a Structural Slowdown?
After a 75% peak-to-trough drawdown and two guidance cuts, Cochlear's FY26 result beat reduced expectations. We weigh the reset case against structural China pricing risk, with a comparable stress-test against...
Is Cochlear a Reset Opportunity or a Structural Slowdown?
After a 75% peak-to-trough drawdown and two guidance cuts, Cochlear's FY26 result beat reduced expectations. We weigh the reset case against structural China pricing risk, with a comparable stress-test against...
Our Locations
Australia
Level 54, 111 Eagle Street
Brisbane City, QLD 4000
Astra Capital Asset Management
Pty Ltd
ACN 627079574
Singapore
68 Circular Road, #02-01
Singapore 049422
Astra Capital Asset Management (Singapore) Pte Ltd
UEN 202605889H